BY MARK SCHOLZ, MD
Everyone is
excited about the latest craze in medical technology—genetic analysis of tumor
cells, which I’ll call GAT for short. The scientific progress that has been
made with GAT in my opinion is the second most
exciting area of advancement in medical technology today (see further below for
more about the first most exciting area). GAT technology is already being
commercialized for use in the medical marketplace in products like Prolaris
and Oncotype. This technology is able to
predict the aggressiveness of prostate cancers, enabling us to differentiate
between the men who need immediate treatment and those who can postpone
treatment safely.
The predictive power of GAT is certainly exciting, but there is already an
effective form of genetic testing available that has been around for more
than 40 years, the Gleason scoring system. The Gleason system relies on the
visual appearance of cells under the microscope to draw conclusions about their
inner genetic makeup. In the medical world, using the visual appearance of the
cancer cells is called phenotypic
analysis. GAT is genotypic
analysis. Drawing conclusions about underlying genetic makeup by simple
visual assessment is a pervasive in human experience. In courtship, we
rely on phenotypic analysis of the underlying genetic make-up of potential
spouses to form an opinion about their suitability as potential mates.
Perusal of the genetic pool of immediate family members provides further
insight.
So how can Gleason score draw conclusions about the underlying genetic
potential for tumor aggressiveness simply by looking at the appearance of cells
under a microscope? The answer is to do a comparison of the visual
appearance of cancer cells with the appearance of normal prostate cells. Normal
cells in the prostate perform varied functions but still work together as a
team. Specifically, healthy cells form into definable structures called
glands. In these glands some cells manufacture prostatic fluid, a complex
liquid comprising the ejaculate for the sperm to swim in. Other cells
organize to form ducts, a piping system to drain the fluid from the outer
periphery of the gland and channel it into the middle of the prostate so that a
large quantity of fluid can be expelled through the urethra at just the right
moment. All of these different cells work as a team and coexist in the
prostate functioning together in a structured glandular arrangement.
When a
trained pathologist looks at tumor cells under the microscope he grades them by
the degree of cellular disorder. He is asking himself the question, “How
much do these cells retain the normal glandular characteristics of the prostate
gland?” If a cross section of the tumor looks like an unbroken sheet of
uniform cells, the cancer is high-grade; the cells have lost their ability to
cooperate with each other and form glands. The cancer cells have been honed
down into little race cars with only one mission, to aggressively pursue its
own replicative destiny. When tumors have this appearance they are graded as a
Gleason 9 or 10. On the other hand, if the appearance of the tumor shows
residual glandular components, it is less aggressive, perhaps a Gleason 7.
Gleason 6 “cancer,” the type the one that never spreads, looks almost like
normal prostate gland tissue.
Predicting
future tumor behavior is obviously very important. How fast will it grow?
Is it likely to spread? How well can it be expected to respond to treatment? As
a result of decades of experience, doctors have learned to use the Gleason
scoring system to accurately predict the long-term outcome in individual
patients. The new GAT tests represent an important additional refinement,
further enhancing our ability to predict the future behavior of an individual
cancer. GAT holds one even bigger promise. In the future we believe GAT
testing will be a powerful aid in the selection of targeted therapy, i.e.,
picking cancer treatments with anticancer activity tailored to individual tumor
types. This hope, however, will have to be postponed until our limited
armamentarium of effective treatments is further expanded.
Now, what is
it that I consider to be the most exciting
area of medical progress? Since I am an impatient type of guy, someone who is
looking for quick results, I find immunotherapy more exciting than GAT. To
fully exploit the potential of GAT we will need to invent new pills for each of
the myriad of genetically different tumor types. Immunotherapy on the other
hand comes with its own “built-in” GAT system that enables it to target the
unique genetic signature of individual cancer cells. The immune system is so
smart, all we have to do is “flip the switch on” and starts cranking out
genetically targeted anticancer therapy. Recent developments in the field of
immunology are truly mind-boggling and hold promise for a big revolution in
cancer therapy within the next 5-10 years. I’ll try to address some of
these recent advances in an upcoming blog.
No comments:
Post a Comment